Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Kidney Neoplasms

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00091611

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

First Posted Date: 2004-03-29

Last Posted Date: 2012-06-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00080353

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Interleukin-2 (IL-2)
Drug: Montanide ISA 51

First Posted Date: 2003-04-28

Last Posted Date: 2012-10-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 138

Registration Number: NCT00059475

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2003-03-25

Last Posted Date: 2016-12-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 92

Registration Number: NCT00056797

Locations: 🇺🇸
NY Presbyterian Weill Cornell Medical Center, New York, New York, United States

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2002-12-18

Last Posted Date: 2013-11-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 620

Registration Number: NCT00050726

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇩🇰
Hvidovre University Hospital@@@Copenhagen, Denmark, Copenhagen, Denmark

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Phase 2

Completed

Conditions: Melanoma
Neoplasm Metastasis

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 141

Registration Number: NCT00001705

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Recombinant interleukin-2 (rIL-2)

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4150

Registration Number: NCT00004978

Locations: 🇺🇸
Cathedral Healthcare System, St. Michael's Med. Ctr. CRS, Newark, New Jersey, United States
🇺🇸
The Early Intervention Program at Kennedy Hosp. CRS, Voorhees, New Jersey, United States
🇨🇦
Toronto Gen. Hosp. Infectious Diseases CRS, Toronto, Ontario, Canada

and more 245 locations

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma
Neoplasm Metastasis

Interventions: Drug: IL-2
Procedure: Apheresis
Biological: Abl cells
Drug: Montanide ISA-51
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: GCSF (Growth colony stimulating factor)

First Posted Date: 1999-11-04

Last Posted Date: 2012-12-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 170

Registration Number: NCT00001832

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Ewing's Sarcoma
Rhabdomyosarcoma

First Posted Date: 1999-11-04

Last Posted Date: 2019-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001564

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Phase 2

Completed

Conditions: Hodgkin's Disease
Non Hodgkin's Lymphoma

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT00001430

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy